Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S
0,49 %
3,060 DKK
0,02
Kurs
3,060
Hög
3,095
Förändring
0,49 %
Låg
3,030
Uppdaterad
17:10:00
Öppen
3,050
Factsheet for Veloxis Pharmaceuticals A/S
Company Profile
Description
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company. It develops products and technology to improve the lives of transplant patients. The firm's products and technology include Envarsus XR and meltdose technology. The company is focused on the direct commercialization of its products in the United States and expansion of partnerships for markets globally and acquisition of assets utilized in transplant patients and by adjacent medical supplies. Geographically, the company operates in the United States, Europe and Other countries, of which key revenue is derived from the United States.
Key Stats
Website: http://www.veloxis.com
Headquarter country: Denmark
Employees: 29
Market Cap (at close 19-07-2019): DKK 5B
Fiscal Year Ends: december
Stats

Stats 2018 2017 2016 2015 2014
Price/Earnings
Forward Price/Earnings
Price/Free Cash Flow
Return on Assets -8,90 -26,60 -39,20 -73,90 -10,50
Return on Equity -106,40 -123,00 -86,90 -94,70 -12,80
Return on Invested Capital -1,30 -27,10 -37,70 -94,60 -12,80
Dividend


Dividend/Share:
Ex. Dividend Date:0001-01-01
Trailing Dividend Yield:
Payout Ratio:0,00
Date Currency Amount
Income Statement

Revenue 2018 2017 2016 2015 2014
Total Revenue 39,49 30,17 9,19 2,07 20,15
Gross Profit 0,03 0,02 0,01 0,00 0,02
Gross Margin % 79,95% 82,76% 67,16% -6,99% 97,37%
Operating Expenses 2018 2017 2016 2015 2014
EBITDA -5,00 -8,00 -28,00 -26,00 -6,00
Net income -5,00 -10,00 -10,00 -26,00 -6,00
Basic Earnings Per Share 0,00 -0,01 -0,01 -0,02 0,00
Operating Income -0,01 -0,01 -0,03 -0,03 -0,01
Operating Margin % -14,78% -27,71% -312,90% -1 392,93% -47,49%
Cash Flow

Cash Flow 2018 2017 2016 2015 2014
Operating Cash Flow -11,00 -8,00 -28,00 -26,00 -13,00
Capital Expenditures 0,00 -1,00 0,00 0,00 0,00
Free Cash Flow -12,00 -8,00 -28,00 -26,00 -13,00
Balance Sheet

Assets 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Current Assets 48,90 20,78 10,61 21,18 47,08 63,86
Long Term Assets 28,21 21,14 19,27 0,63 0,88 0,71
Total Assets 77,12 41,92 29,88 21,82 47,96 64,57
Liabilities 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Total Current Liabilities 12,60 10,79 5,87 8,69 6,61 12,92
Long Term Liabilities 25,82 13,82 0,00
Total Liabilities 36,61 19,69 8,69
Equity 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Retained Earnings -15,73 -72,75 -67,73 -71,14 -52,59 -54,84
Treasury Stock
Total Stockholder Equity 4,61 5,32 10,20 13,13 41,35 51,65
Net Tangible Assets 4,57 5,24 10,08 12,99 41,16 51,56